Skip to Content

Daklinza (daclatasvir) Disease Interactions

There is 1 disease interaction with Daklinza (daclatasvir):

Major

Daclatasvir (applies to Daklinza) cirrhosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis

In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates. In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir. Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up. Consider appropriate management for patients with HBV infection as clinically indicated.

Daklinza (daclatasvir) drug interactions

There are 174 drug interactions with Daklinza (daclatasvir)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.